Page last updated: 2024-12-06
4-methylaminobenzoic acid
4-methylaminobenzoic acid, also known as 4-amino-benzoic acid, is an organic compound with the formula C7H8NO2. It is a white crystalline solid that is soluble in water. 4-methylaminobenzoic acid is used as an intermediate in the synthesis of various pharmaceuticals and dyes. It is also used as a food additive and a photographic developer. Research on 4-methylaminobenzoic acid focuses on its potential use in the treatment of various diseases, including cancer, diabetes, and Alzheimer's disease. It has been shown to have antioxidant and anti-inflammatory properties.'
```
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 66345 |
| CHEMBL ID | 3098156 |
| CHEBI ID | 7308 |
| SCHEMBL ID | 98312 |
| SCHEMBL ID | 10643579 |
| SCHEMBL ID | 18881012 |
| MeSH ID | M0071095 |
Synonyms (58)
| Synonym |
|---|
| AC-18777 |
| 4-(methylamino)benzoic |
| BIDD:GT0254 |
| IDI1_014737 |
| OPREA1_065286 |
| p-methylaminobenzoic acid |
| benzoic acid, p-(methylamino)- |
| n-methyl-4-aminobenzoic acid |
| nsc102506 |
| p-(methylamino)benzoic acid |
| benzoic acid, 4-(methylamino)- |
| 4-(methylamino)benzoic acid |
| 4-(n-methylamino)benzoic acid |
| 10541-83-0 |
| nsc-102506 |
| 4-methylaminobenzoic acid |
| n-methyl-4-aminobenzoate |
| C03522 |
| 4-(methylamino)benzoic acid, 97% |
| MAYBRIDGE3_003350 |
| inchi=1/c8h9no2/c1-9-7-4-2-6(3-5-7)8(10)11/h2-5,9h,1h3,(h,10,11 |
| 535DA2AE-A158-46F5-AFD0-CA8F157E14D4 |
| HMS1440I06 |
| M0267 |
| A801236 |
| 4-methylamino-benzoic acid |
| unii-aru98z0ozy |
| aru98z0ozy , |
| nsc 102506 |
| ai3-62242 |
| einecs 234-121-7 |
| AKOS005202998 |
| FT-0619057 |
| FT-0619056 |
| SCHEMBL98312 |
| p-methylamino-benzoic acid |
| 4-(methylamino) benzoic acid |
| 4-(methylamino)-benzoic acid |
| 4-methylamino benzoic acid |
| p-(n-methylamino)benzoic acid |
| chebi:7308 , |
| CHEMBL3098156 |
| p-carboxy-n-methylaniline |
| DTXSID8065117 |
| SCHEMBL10643579 |
| W-200739 |
| STR03499 |
| mfcd00002535 |
| 81P , |
| SCHEMBL18881012 |
| F16175 |
| 4-(methylamino)benzoicacid |
| SY011239 |
| CS-0029513 |
| Q27107471 |
| AMY23261 |
| EN300-51519 |
| Z727574068 |
Drug Classes (1)
| Class | Description |
|---|
| aminobenzoic acid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1234441 | Drug level in phosphate buffer treated with (Z)-1-(2-cyano-5-(4-(methylamino)benzoyloxy)-4-nitrophenoxy)-3,3-dimethyltriaz-1-ene 2-oxide at 1 uM at pH 7.4 at 37 degC after 30 secs by LC-MS analysis in presence of GSH | 2015 | Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
| PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells. |
| AID1060463 | Inhibition of Sir2p in yeast DMY2844 assessed as growth inhibition after 48 hrs | 2014 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
| Evaluation of benzoic acid derivatives as sirtuin inhibitors. |
| AID1234453 | Drug level in phosphate buffer treated with (Z)-3,3-dimethyl-1-(5-(4-(methylamino)benzoyloxy)-2,4-dinitrophenoxy)triaz-1-ene 2-oxide at 1 uM at pH 7.4 at 37 degC after 1 to 30 mins by LC/MS-MS analysis | 2015 | Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
| PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells. |
| AID1234430 | Drug level in phosphate buffer treated with (Z)-3,3-dimethyl-1-(5-(4-(methylamino)benzoyloxy)-2,4-dinitrophenoxy)triaz-1-ene 2-oxide at 1 uM at pH 7.4 at 25 degC by HPLC trapping method | 2015 | Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
| PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 13.28 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 5.08 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |